Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,444 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,444 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02532010 | Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML(Pacritinib) | Phase 2 | terminated | Aug 25, 2015 | Weill Medical College of Cornell University | The study was put on clinical hold by the sponsor since Feb 9th 2016, and was later decided not to… | Funding |
| NCT02419469 | Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute… | Phase 2 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01326728 | Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation | — | terminated | Mar 31, 2011 | National Cancer Institute (NCI) | A replacement protocol was created to replace this current version of protocol. | Other (stated, no rule matched) |
| NCT01596127 | Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System | Phase 1 / Phase 2 | terminated | May 10, 2012 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01162031 | Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia | Phase 2 | withdrawn | Jul 14, 2010 | Stanford University | no accrual | Enrollment / accrual |
| NCT01835288 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | withdrawn | Apr 18, 2013 | Stanford University | not stated | Not stated |
| NCT01195480 | CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)(CD19TPALL) | Phase 1 / Phase 2 | terminated | Sep 6, 2010 | University College, London | Due to lack of biological efficacy and CD19 CAR CTL persistence | Efficacy / futility |
| NCT02635074 | Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Dec 18, 2015 | Steven E. Coutre | safety | Safety / toxicity |
| NCT02848248 | A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia | Phase 1 | terminated | Jul 28, 2016 | Seagen Inc. | not stated | Not stated |
| NCT00118196 | Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or… | Phase 2 | terminated | Jul 11, 2005 | Medical University of South Carolina | Due to limited resources available to conduct study | Other (stated, no rule matched) |
| NCT00290407 | Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic… | Phase 2 | terminated | Feb 13, 2006 | University of Louisville | terminated due to lack of accrual | Enrollment / accrual |
| NCT02723435 | Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | Phase 2 | withdrawn | Mar 30, 2016 | Stanford University | Logistical and administrative issues | Other (stated, no rule matched) |
| NCT02905994 | Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia | Phase 1 | withdrawn | Sep 19, 2016 | Massachusetts General Hospital | Funding Withdrawn | Funding |
| NCT00014560 | Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma… | Phase 1 | terminated | Jul 30, 2003 | Dartmouth-Hitchcock Medical Center | Medarex (supplier of BsAb) stopped study due to toxicities experienced at other sites on unrelated… | Safety / toxicity |
| NCT00984165 | Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic… | Phase 2 | terminated | Sep 25, 2009 | National Cancer Institute (NCI) | Terminated due to slow accrual, PI left NIH and primary endpoint not met. | Investigator |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood… | Phase 2 | terminated | Aug 24, 2016 | Emory University | not stated | Not stated |
| NCT01612988 | Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL(BOMP) | Phase 2 | terminated | Jun 6, 2012 | French Innovative Leukemia Organisation | Other drugs others studies | Other (stated, no rule matched) |
| NCT00626626 | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation | Phase 1 / Phase 2 | terminated | Feb 29, 2008 | Milton S. Hershey Medical Center | Investigator decision | Investigator |
| NCT01755325 | Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo… | Phase 3 | suspended | Dec 24, 2012 | Junmin Li | not enough patients | Other (stated, no rule matched) |
| NCT02680951 | Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor… | Phase 1 | withdrawn | Feb 12, 2016 | Emory University | Withdrawn due to lack of participants. | Other (stated, no rule matched) |
| NCT02462265 | Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid… | Phase 2 | suspended | Jun 4, 2015 | Oshadi Drug Administration | not stated | Not stated |
| NCT00593554 | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies | Phase 2 | terminated | Jan 15, 2008 | Sherif S. Farag | Slow accrual | Enrollment / accrual |
| NCT01770158 | Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute… | — | terminated | Jan 17, 2013 | University of Ulm | Recruitment goal cannot be achieved any more as only 8 patients have been recruited since start of… | Enrollment / accrual |
| NCT01907815 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia | Phase 2 | terminated | Jul 25, 2013 | National Cancer Institute (NCI) | Lack of efficacy. | Efficacy / futility |
| NCT02519712 | Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized… | N/A | terminated | Aug 11, 2015 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT02020109 | Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia | — | withdrawn | Dec 24, 2013 | Maastricht Radiation Oncology | Logistics and financial | Funding |
| NCT01801046 | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | Phase 1 | terminated | Feb 28, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT02204020 | Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS(UPCI 13-165) | Phase 2 | withdrawn | Jul 30, 2014 | University of Pittsburgh | Lack of interest with investigators - no subjects enrolled | Enrollment / accrual |
| NCT01271010 | A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants… | Phase 4 | terminated | Jan 6, 2011 | Hoffmann-La Roche | not stated | Not stated |
| NCT01069432 | Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic… | — | withdrawn | Feb 17, 2010 | Dartmouth-Hitchcock Medical Center | IRB delayed their review for an extensive period of time. Funding for this protocol is no longer… | Funding |
| NCT00113646 | Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for… | Phase 2 | terminated | Jun 10, 2005 | Massachusetts General Hospital | Expiration of MEDI-507 | Other (stated, no rule matched) |
| NCT00113828 | Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for… | Phase 2 | terminated | Jun 13, 2005 | Massachusetts General Hospital | Insufficient accrual | Enrollment / accrual |
| NCT02269579 | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine:… | Phase 2 | withdrawn | Oct 21, 2014 | Jazz Pharmaceuticals | not stated | Not stated |
| NCT02419755 | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged… | Phase 2 | terminated | Apr 17, 2015 | St. Jude Children's Research Hospital | Accrual goals were no longer feasible based on restrictions imposed by the DSMB. | Enrollment / accrual |
| NCT03347994 | Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | withdrawn | Nov 20, 2017 | Justin Watts | Discordance in contractual language and terms. | Other (stated, no rule matched) |
| NCT02137889 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or…(VAY736Y) | Phase 1 | terminated | May 14, 2014 | Novartis Pharmaceuticals | Study terminated on 04Oct2013 for business reasons after being on hold for 10 months. Early… | Safety / toxicity |
| NCT02198482 | Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly… | Phase 2 | terminated | Jul 23, 2014 | University of Ulm | development program of study drug volasertib was stopped by Boehringer Ingelheim due to… | Drug supply |
| NCT02371590 | Lenalidomide and Obinutuzumab for Previously Untreated CLL | Phase 2 | withdrawn | Feb 25, 2015 | University of California, San Diego | Study Not Activated Due to Contract Issues | Other (stated, no rule matched) |
| NCT02631252 | Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for… | Phase 1 | terminated | Dec 16, 2015 | Alison Sehgal, MD, MS | Inability to accrue | Enrollment / accrual |
| NCT00268242 | Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia | Phase 2 | terminated | Dec 22, 2005 | The Cleveland Clinic | If \</= 5 of the initial 18 patients had a CR, the study would be stopped. Only 5 patients (21%) of… | Enrollment / accrual |
| NCT01685021 | Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic… | Phase 2 | terminated | Sep 13, 2012 | MorphoSys AG | not stated | Not stated |
| NCT00852709 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated…(POE07-01) | Phase 1 | terminated | Feb 27, 2009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Lack of accrual | Enrollment / accrual |
| NCT02578511 | Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With… | Phase 1 | withdrawn | Oct 19, 2015 | Ehab L Atallah | No enrollment, another competing study and difficult to find the right person to enroll on this… | Enrollment / accrual |
| NCT02856178 | Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML…(SAFEGUARD) | Phase 1 / Phase 2 | withdrawn | Aug 4, 2016 | F2G Ltd | study no longer required | Other (stated, no rule matched) |
| NCT03036046 | Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml…(SAFEGUARDFP) | Phase 1 / Phase 2 | withdrawn | Jan 30, 2017 | F2G Ltd | Study no longer required | Other (stated, no rule matched) |
| NCT02141477 | Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic… | Phase 1 | terminated | May 19, 2014 | M.D. Anderson Cancer Center | Slow Accrual-2 patients were registered Phase I and none in Phase II | Enrollment / accrual |
| NCT02335814 | First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid… | Phase 1 | terminated | Jan 12, 2015 | RAPT Therapeutics, Inc. | Dose escalation completed; Sponsor decision | Sponsor / business decision |
| NCT01446900 | R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia… | Phase 2 | terminated | Oct 5, 2011 | European Institute of Oncology | low rate in patient accrual | Enrollment / accrual |
| NCT02815059 | Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and… | Phase 1 | withdrawn | Jun 28, 2016 | University of Utah | Termination of Investigator Initiated Studies using Ibrutinib | Investigator |
| NCT02200848 | Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic… | Phase 1 | terminated | Jul 25, 2014 | Georgetown University | Recruitment difficulties and toxicity | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Jun 15, 2018source: clinicaltrials